Efloran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efloran

Quick Facts

Property Description
Active ingredient Metronidazole
Form Tablets, Solution for Infusion, Topical Preparations (Gel/Cream)
Pharmacological class Antimicrobial Agent; Nitroimidazole Derivative
General Purpose Elimination of Anaerobic Micro-organisms and Protozoa
Origin Synthetic Drug

Core Identity: Efloran as a Nitroimidazole Antimicrobial Agent

Efloran is a trade name for the synthetic medicine Metronidazole, which is classified as a Nitroimidazole derivative and functions as a highly specific antimicrobial agent. This synthetic drug belongs to a focused group of chemotherapeutic agents developed to address specific infections and is recognized as an essential medicine. Metronidazole is defined as a synthetic antibacterial and antiprotozoal agent, with a general purpose of eliminating both certain pathogenic bacteria and single-celled parasites. This dual-action classification against both bacteria and parasites is a key differentiating feature, allowing its use in varied, yet specifically targeted, infectious processes.


Composition, Origin, and Available Forms

The medicine is a single-ingredient product featuring Metronidazole as the active substance, available in forms suited for both systemic and local administration. As a chemically defined compound, Metronidazole is entirely a synthetic drug, not naturally derived. To ensure effective delivery across different parts of the body, Efloran is manufactured in multiple dosage forms, including tablets for oral use, solution for infusion for intravenous (systemic) delivery, and various topical preparations such as creams, gels, and vaginal inserts for local application. This versatility of pharmaceutical preparations reflects the utility of different administration routes in controlling infection.


General Mechanism and Therapeutic Type

Efloran functions through a mechanism of selective toxicity where the drug is activated only inside the targeted micro-organism, leading to the disruption of the pathogen's DNA. This highly specific action achieves anaerobic micro-organism elimination. The effectiveness of Metronidazole is due to its reduction within susceptible cells, which then damages the cell's genetic material. This unique mechanism of effect provides anaerobic micro-organism elimination for treating infections where these specific agents are present.

Regulatory References

  1. Metronidazole - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Efloran?

Possible Side Effects and Safety Information

The safety profile of Efloran (Metronidazole) is formally classified based on frequency and the body system affected, as documented in regulatory sources like the FDA and EMA. The most Common adverse reactions typically involve the Gastrointestinal System, including metallic taste (dysgeusia), nausea, diarrhea, and headache. In women, vulvovaginal candidiasis is also commonly reported.


System-Organ Classes and Serious Reactions

Adverse effects are grouped into system-organ classes, with significant events reported across the Nervous System and the Skin. Serious, but rare, adverse reactions officially documented include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, and central nervous system effects like encephalopathy and convulsive seizures. Reversible neutropenia and thrombocytopenia have been observed in the Blood and Lymphatic System.


Exposure Patterns and Population Constraints

The official safety information highlights specific exposure-related constraints. A Disulfiram-like reaction (flushing, vomiting, headache) occurs if alcohol or products containing propylene glycol are consumed during therapy and for at least three days after treatment. For prolonged therapy exceeding ten days, regular clinical and laboratory monitoring is advised due to the risk of peripheral or central neuropathy. Specific Population-Specific Safety Notes include a contraindication for use in patients with Cockayne syndrome due to the risk of severe, irreversible hepatotoxicity, and recommendations for monitoring in patients with severe hepatic or end-stage renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Efloran (Metronidazole) necessitates immediate medical attention. The official regulatory profile describes specific clinical manifestations and mandated emergency actions.

Documented Manifestations and Severe Outcomes

Overdose presentations may include gastrointestinal symptoms such as nausea and vomiting, alongside signs of neurological toxicity, including ataxia (lack of coordination). In cases of high-dose or prolonged exposure, more severe effects documented are convulsive seizures and the development of peripheral neuropathy.

A specific, life-threatening risk of severe irreversible hepatotoxicity leading to acute liver failure has been documented in patients with Cockayne Syndrome following systemic use, requiring immediate drug cessation. Patients with severe hepatic impairment also require close monitoring to prevent potential CNS toxicity from drug accumulation.

Official Management and Emergency Response

The regulatory guidance states that no specific antidote is known for Metronidazole overdose. Management is constrained to symptomatic and supportive therapy. Procedures such as hemodialysis are documented as effective for removing the drug and its metabolites from the circulation. The appearance of any abnormal neurological signs and symptoms mandates the prompt evaluation of treatment status. Always seek immediate medical help for any suspected overdose.

Therapeutic Uses of Efloran

What Efloran Treats: Main Uses and Benefits

Efloran (Metronidazole) is commonly used to address specific infections and supports the easing of associated symptoms, which are often related to physical discomfort and can create noticeable physiological strain or interfere with daily functioning.

This medication is applied across therapeutic domains involving anaerobic organisms and protozoa. It is relevant for managing severe systemic conditions like deep abscesses and septicemia, as well as specific localized and parasitic conditions. Common conditions where Efloran is relevant include Amebiasis, Giardiasis, Bacterial Vaginosis, Trichomoniasis, and certain dental infections. The primary focus is on addressing the symptoms that cluster into patterns requiring supportive management.

Quick Fact: Managing symptoms related to Severe Pain and Discharge

How Efloran Supports Symptom Management

This medication is considered relevant for managing serious infections, which typically present with intense pain and high fever—symptoms related to systemic imbalance. Efloran assists with maintaining functional stability during these acute episodes. For symptomatic discomfort, it contributes to easing the overall symptom load by addressing symptoms related to severe intestinal upset, abnormal vaginal discharge, and localized inflammatory pain.

“Efloran helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

In surgical settings, it is commonly used to help with reducing the risk of infections following procedures like colorectal surgery. For chronic inflammatory issues like Rosacea, topical application may assist with the symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Status for Efloran (Metronidazole)

The eligibility for Efloran is strictly governed by regulatory documentation, defining which populations are allowed to use the medicine and which must avoid it based on patient history, co-existing conditions, and physiological status.

Eligibility Status Population/Condition Regulatory Criteria
Contraindicated (Must Not Use) Hypersensitivity Prior allergy to metronidazole or any nitroimidazole derivative.
Genetic Conditions Patients with Cockayne Syndrome must not use this medicine due to the severe risk of fatal hepatotoxicity.
Substance Use Use is prohibited in patients who have consumed alcohol during therapy or for up to 72 hours after, or who have taken disulfiram within the last two weeks.
Restricted Use (Conditional) Organ Function Severe Hepatic Impairment requires use with caution and an official dose reduction due to decreased drug clearance. Patients with End-Stage Renal Disease must be monitored for metabolite accumulation.
Age-Based Limits Use in the general pediatric population is not established for many oral forms, and older adults require caution due to an increased risk of unwanted effects.
Pregnancy/Lactation Use is generally advised to be avoided during the first trimester of pregnancy. While secreted into milk, use during breastfeeding requires infant monitoring.

The regulatory profile establishes definitive contraindications for high-risk patients and mandates caution or monitoring for those with impaired organ function or during sensitive physiological states like pregnancy, thereby structuring the entire eligibility framework.

What should I know about interactions with other medicines?

Efloran (metronidazole) can interact with several other medications and products. It is essential to inform your healthcare provider about all prescription and non-prescription drugs, supplements, and herbal remedies you are taking.

Medication Interactions

The simultaneous use of Efloran with certain medications can lead to potentially serious effects. Interactions may require dose adjustments or intensified monitoring by a healthcare professional, or the combination may need to be avoided entirely. Key interacting medications include:

Interacting Drug Potential Effect Management
Warfarin (and other oral anticoagulants) Increased risk of bleeding due to enhanced anticoagulant effect. Close monitoring of INR; potential dose reduction for the anticoagulant.
Lithium Increased blood levels of lithium, raising the risk of toxicity. Frequent monitoring of lithium blood levels and signs of toxicity.
Phenobarbital or Phenytoin (for epilepsy) Decreased effectiveness of Efloran. Dose adjustment of Efloran may be necessary.
Cimetidine (for stomach acid) May increase the concentration of Efloran in the body, raising the risk of side effects. Monitoring for increased side effects.
Disulfiram May cause psychotic reactions and should generally be avoided for two weeks before starting Efloran. Avoid the combination.

Alcohol and Other Products

Consumption of alcohol (including alcohol-containing medications, like some cough syrups and mouthwashes) during treatment with Efloran and for at least 72 hours after the last dose is strictly discouraged. This combination can cause a severe reaction known as a disulfiram-like effect, which includes flushing, headache, nausea, vomiting, sweating, and a rapid heartbeat. Products containing propylene glycol should also be avoided for the same duration.

Mechanism of Action

Efloran (Metronidazole) operates through a unique selective toxicity mechanism that relies on chemical activation. The drug is a prodrug that remains inert until it encounters the low-oxygen (low-redox) environment found within susceptible anaerobic microbes. Specific microbial electron transport proteins, such as Ferredoxin, donate an electron to the Metronidazole nitro group ( NO2). This reduction generates a highly reactive nitro free radical—the true cytotoxic agent. The short-lived radical immediately attacks the microorganism’s DNA, causing fragmentation and strand breakage. This physicochemical destruction of the genetic blueprint halts vital cellular functions and triggers concentration-dependent microbial cell death. The mechanism is strictly limited by oxygen, which competes for electrons and neutralizes the active radical (futile cycling), rendering the drug functionally ineffective against aerobic organisms.

Dosage and Administration Information

Efloran, a formulation of Metronidazole, is administered through several officially approved pathways depending on the therapeutic requirement. Systemic administration for treating deep infections utilizes oral forms, such as immediate-release tablets, or the intravenous (IV) solution for infusion. Localized applications are managed using topical preparations or intravaginal inserts.

Dosing schedules are highly specific to the context of use. For severe anaerobic infections, the regimen typically begins with a loading dose of 15 mg/kg, followed by a maintenance dose of 7.5 mg/kg every six or eight hours. Conversely, single-dose regimens, such as a 2 gram oral dose, are approved for certain parasitic conditions like Trichomoniasis.

Timing in relation to food is critical for proper use and absorption. Immediate-release tablets must be taken with or after meals to support patient tolerance. However, extended-release forms must be taken on an empty stomach, specifically one hour before or two hours after eating.

Specific procedural constraints govern administration. The IV solution must be delivered as a slow infusion over a period of 30 to 60 minutes, and the infusion container should not be mixed with other additives. Administration protocols include high-level dose adjustments, such as a 50% reduction in the presence of severe hepatic impairment, while the standard course duration for most infections ranges from 7 to 10 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Efloran

Efloran (Metronidazole) has been evaluated in clinical research settings. Research has explored its classification and evaluation in contexts involving anaerobic bacteria and protozoa. The research landscape consists primarily of Randomized Controlled Trials (RCTs), comparative studies, and aggregated data from meta-analyses and systematic reviews that have been reviewed by regulatory bodies. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.


Evidence for Use in Systemic Anaerobic Bacterial Infections

Research has focused on the use of Efloran in hospitalized adults and adolescents studied for serious infections where anaerobic bacteria are involved. Randomized controlled trials typically monitored objective measures such as the resolution of fever and pain indicators, the need for further antibiotic intervention, and the rate of the change in microbiological status. Studies reported measurements of the change in microbiological status in the short-term following treatment. Data describe patterns of the measured change in clinical status in the observed populations that received Efloran as part of the treatment regimen. Long-term effects are not fully established for these acute conditions.


Research Evidence for Protozoal and Parasitic Conditions

For parasitic infections, including Amebiasis and Giardiasis, Efloran was evaluated in clinical trials that included both adults and children. Research examined outcomes related to the change in parasite status and monitored the change in severe intestinal upset. For Trichomoniasis, studies monitored the change in specific clinical signs and assessed the change in parasite status in symptomatic females and their male sexual partners. Scientific reports document the increasing reporting of metronidazole-resistant isolates for Giardiasis and Trichomoniasis. This is a scientific challenge that may influence observed long-term outcomes in some populations.


What Remains Undefined and Areas of Research Uncertainty

A primary area of ongoing uncertainty is the clinical impact of emerging metronidazole resistance. Furthermore, follow-up durations were limited in many of the key studies. Therefore, there is limited information for long-term outcomes regarding the recurrence of infection or the maintenance of symptom control beyond the immediate treatment phase. Finally, evidence quality varies across studies, and while there is generally consistent evidence for short-term microbiological status change, comparative evidence is lacking for many new or alternative agents in certain specific contexts.

Key Studies & References

  1. Metronidazole and Other Antibiotics for Anaerobic Infections (Review of efficacy in various sites)
  2. A Meta-analysis of the Effectiveness of Albendazole Compared with Metronidazole as Treatments for Infections with Giardia duodenalis (Discusses metronidazole resistance and adherence issues)
  3. Metronidazole - eEML - Electronic Essential Medicines List (WHO context on availability and forms)

Frequently Asked Questions (FAQ)

Common questions about Efloran (FAQ)

Q: How quickly should I start to feel better after starting Efloran?

A: Official information indicates that Efloran is absorbed rapidly into the body after use. While the medicine reaches its highest concentration quickly, it may still take a few days before an improvement in symptoms is generally noticeable. The exact timing can vary from person to person.


Q: Can Efloran affect the effectiveness of birth control pills?

A: Drug interaction summaries have noted that Efloran has been associated with case reports of contraceptive failure, although this is not a universally confirmed effect. Official guidance describes that healthcare professionals may recommend an alternative form of birth control be used during treatment.


Q: Is it necessary to finish the entire prescribed course of Efloran even if symptoms improve quickly?

A: Official regulatory guidelines communicate that it is important to complete the full course of treatment as prescribed. This recommendation is made because stopping treatment prematurely, even if symptoms improve quickly, can lead to the recurrence of the original infection.


Q: Are there any known interactions between Efloran and herbal supplements?

A: Official sources typically do not report specific problems with common herbal remedies or nutritional supplements alongside Efloran. However, any liquid or oral herbal product is covered by the warning to check for possible alcohol content, as alcohol is strictly forbidden with this medicine.


Q: Why is Efloran sometimes associated with a risk of pancreatitis?

A: Pancreatitis, which is inflammation of the pancreas and can cause severe stomach pain, is listed in official regulatory documents as a possible, though rare, serious adverse reaction. This is one of the more significant, infrequent effects that has been documented.


Q: Is Efloran used to treat infections caused by parasites?

A: Official product information describes Efloran as an antiprotozoal agent. This means it has documented activity against certain single-celled organisms, or protozoa, which are one type of parasite. Its general purpose is defined as the elimination of both anaerobic microorganisms and protozoa.


Q: Why does Efloran sometimes cause urine to appear darker than normal?

A: Darkening or a reddish-brown discoloration of the urine has been reported as a documented effect while taking Efloran. Official information indicates that this change is thought to be caused by a metabolite (a substance created when the body processes the drug) and is generally considered to have no clinical significance.


Q: What is the risk of developing a yeast infection after a course of Efloran?

A: The risk of developing a yeast infection is commonly reported, particularly vulvovaginal candidiasis (a type of yeast infection) in women. Oral thrush, another form of candidiasis, is also reported as a possible adverse effect. This can happen because the medicine eliminates certain bacteria in the body.


Q: Can Efloran interact with over-the-counter pain relief medications?

A: Official drug interaction summaries do not typically list specific interactions with common over-the-counter pain relievers like ibuprofen or NSAIDs. However, the documentation stresses the importance of informing a healthcare provider about all medicines, including OTC products.


Q: What is the official guidance on using Efloran during the first trimester of pregnancy?

A: Guidance on use during pregnancy may vary across different regulatory bodies. Official recommendations note that use during the first trimester of pregnancy is typically restricted or reserved for cases where other treatment options are deemed inadequate.


Q: What is the guidance for using Efloran while breastfeeding?

A: The medicine is secreted into breast milk. Official guidance from health authorities includes notes on monitoring the infant for changes, such as in bowel habit, feeding, or skin rash. Standard doses are generally described as acceptable for healthy, full-term infants.


Q: Is Efloran generally used in older adult populations?

A: Official studies have not shown specific problems that would strictly limit its usefulness in older adults. However, caution may be required in this population due to the possibility of unwanted effects and age-related changes in liver function, which may necessitate potential dose adjustment.


Q: Is there any difference in how Efloran works in a tablet versus a cream formulation?

A: The systemic form (tablet) is known to work by disrupting the target organism's DNA. For topical forms (cream or gel), the full working mechanism is not completely known, but scientific descriptions suggest it involves a combination of both antibacterial effects and anti-inflammatory properties at the site of application.


Q: Can a person develop a skin rash or hives as a reaction to Efloran?

A: Official warnings note that signs of an allergic reaction, including the development of a skin rash or hives (urticaria), are possible. These types of symptoms are listed in the official instructions that describe when treatment cessation and evaluation are necessary.

How should Efloran be stored and disposed of?

How to Store and Dispose of Efloran (Metronidazole)

Official regulatory documents define specific conditions for storing metronidazole to maintain product stability and effectiveness.

Storage Requirements

Temperature and Protection: Efloran oral tablets must be stored below 25 C (77 F) or below 86 F (30 C) and must be protected from light. The intravenous solution requires storage at 20^circ to 25 C (68^circ to 77 F) and must be kept in its original container.

Handling and Safety: Keep the tablets in their container, tightly closed, and away from excess heat and moisture. All forms of this medication must be stored out of sight and reach of children.

Disposal Instructions

Unused or expired Efloran must be disposed of in accordance with local requirements. The preferred method is using a drug take-back option. If take-back is unavailable, specific regulatory guidelines for household trash disposal must be followed, including mixing the medicine with an unappealing substance and placing it in a sealed bag before discarding; do not crush pills.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Efloran found in:

A-Z Index: